This is a significant clinical win that directly strengthens Vafseo's competitive positioning against ESAs in the U.S. dialysis market. The superiority finding on hospitalizations (not just non-inferiority) is a high-value data point for formulary negotiations and could drive market share acceleration. Traders should watch for Akebia's next quarterly update for any early revenue impact signals, and monitor for the planned scientific meeting presentation where full data will be disclosed. The stock has limited float and high institutional bullishness (91% analyst Buy rating), so positive catalyst could amplify upside.
Drug in focus
AKBA drug pipeline →Vafseo
● Neutral Named in this 8-K- Impact
- Phase
- Approved by FDA (Phase 3b TIW-dosing study ongoing)
- Time to market
- Already on the market (FDA approved March 27, 2024; commercial launch January 2025)
- Next catalyst
- None dated
What to watchWatch Q4 2026 for Phase 3b TIW-dosing topline data, positive results could unlock label expansion for three-times-weekly dosing, a commercial accelerator. The bigger overhang is the stalled non-dialysis expansion path (VALOR terminated Oct 2025), which caps the addressable market. Monitor quarterly Vafseo net revenue growth and whether Vafseo can offset the Auryxia generic erosion (Teva launched generic March 2026).
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 30 $1.14entry
- T+1 · 5mo ago +6.14%α +6.28% · $1.21
- T+5 · 4mo ago +14.04%α +13.43% · $1.30
- T+20 · 4mo ago +12.28%α +13.31% · $1.28
- T+60 · 8w ago −18.19%α −21.76% · $0.9326
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Akebia Therapeutics and U.S. Renal Care announced that the VOICE trial (Vafseo vs. ESA in 2,116 dialysis patients) met its predefined stopping criteria at interim analysis with a win odds of 1.16 (p=0.0016), establishing superiority on the composite endpoint of all-cause mortality and hospitalization. The trial was stopped early based on the recommendation of the Independent Data Monitoring Committee, driven by a statistically significant reduction in hospitalizations (IRR 0.90, p<0.05), with no difference in mortality. This is a strong clinical catalyst, the trial validates Vafseo's safety differentiation over ESAs using a three-times-weekly dosing regimen and directly supports Akebia's commercial positioning in the $306M market cap company's sole marketed product.
Key Facts
- VOICE trial enrolled 2,116 patients; stopped early by IDMC after meeting prespecified superiority stopping criteria.
- Primary composite endpoint win odds 1.16 (95% CI 1.06–1.28, p=0.0016), establishing non-inferiority and superiority vs. ESA.
- Hospitalizations per patient-year: 1.11 (Vafseo) vs 1.23 (ESA), incidence rate ratio 0.90 (95% CI 0.824–0.988), p<0.05.
- Mortality: 8.77% vs 8.78% per 100 patient-years, incidence rate ratio 1.00 (95% CI 0.718–1.391), not statistically significant.
- Data cutoff date: June 1, 2026. Filing date: June 30, 2026.
- Vafseo (vadadustat) is the only oral HIF-PHI approved in the U.S. for anemia due to CKD in dialysis patients; approved March 2024, launched January 2025.
- Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting.
Financial Impact
Materially positive for Akebia's commercial prospects, Vafseo is the company's only marketed product. Superiority vs. ESA on hospitalization in a U.S. dialysis-specific trial supports formulary access, label differentiation, and potential dosing-regimen expansion. No specific financial figures quantified in this filing.
Risk Factors
- Full trial results not yet presented at a scientific meeting; interim analysis may differ from final data.
- Open-label design introduces potential bias; superiority driven by hospitalization, not mortality benefit (mortality neutral).
- Vafseo carries a Boxed Warning for increased risk of death, MI, stroke, VTE, and vascular access thrombosis (MACE risk).
- Commercial adoption still early (launched Jan 2025); sales trajectory not disclosed here.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001517022-26-000047 |
| Document: akba-20260630.htm | 0001517022-26-000047 |
| Document: 0001517022-26-000047-index-headers.html | 0001517022-26-000047 |
| Document: 0001517022-26-000047-index.html | 0001517022-26-000047 |
| Document: 0001517022-26-000047.txt | 0001517022-26-000047 |
Track record
11 reports on AKBA
2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +9.74% at T+5 after the Oct 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry $0.4700 Now $0.4490 −4.47% settles Nov 17
- Nov 16, 2026today Press Release Neutral 3/10 Entry $0.4775 Now $0.4490 −5.97% settles Nov 17
- Nov 5, 202611d ago 8-K Bearish 5/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $0.4255 to $0.4013 Now $0.4490 −5.52% ▲ +5.69% +6.00% vs SPY
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $0.6438 to $0.6604 Now $0.4490 −30.26% ▲ +2.58% +2.02% vs SPY
- Oct 23, 202624d ago 8-K Bearish 7/10 Entry $0.6438 to $0.6604 Now $0.4490 +30.26% ▼ −2.58% −2.02% vs SPY
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.7020 to $0.6955 Now $0.4490 −36.04% ▼ −0.93% −1.21% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9800 to $0.9326 Now $0.4490 −54.18% ▼ −4.84% −4.12% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Viewing Entry $1.14 to $1.21 Now $0.4490 −60.61% ▲ +6.14% +6.28% vs SPY
- Apr 30, 202628w ago Press Release Neutral 1/10 Entry $1.40 Now $0.4490 −67.93% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers